Inhibition of the JAK-STAT pathway, for example, has emerged as a viable treatment regimen for several conditions including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease [50]. Here, SOAT1 is linked to rheumatoid arthritis.